Hetram 2mg Tablet contains Perampanel, an antiepileptic agent indicated for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy. Perampanel acts as a selective non-competitive antagonist of the AMPA receptor on postsynaptic neurons, thereby reducing neuronal excitability and seizure propagation. Hetram is typically prescribed as adjunctive therapy in patients aged 12 years and older who have not achieved adequate seizure control with other antiepileptic drugs. The 2mg dosage allows for careful titration to minimize adverse effects, which may include dizziness, somnolence, headache, irritability, and gait disturbances. Caution is advised in patients with a history of psychiatric disorders, as Perampanel has been associated with behavioral changes, including aggression and mood alterations. Hepatic impairment may necessitate dose adjustments, and concurrent use with enzyme-inducing antiepileptic drugs can reduce Perampanel plasma concentrations, potentially requiring dosage modification. Hetram should be administered orally once daily at bedtime to optimize tolerability. Regular monitoring of seizure frequency and adverse effects is recommended to ensure therapeutic efficacy and safety. Patients should be counseled on the importance of adherence and informed about potential side effects and drug interactions.